ACXP

Conviction 0HealthcareScan · Mon, Aug 10, 2026

ACXP$1.52-1.30%

ResistanceSupportVol 14

Vol MA14 82.18K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Acurx Pharmaceuticals, Inc.PHARMACEUTICAL PREPARATIONSwww.acurxpharma.com ↗

Price1.52

Change-1.30%

Gap+0.00%

Rel volume0.20×

Avg volume87.86K

Avg $ vol133.03K

SMA 201.49

SMA 501.55

SMA 2002.78

Price vs 50-2.15%

Price vs 200-45.31%

MA stackbearish

50/200 cross—

Supertrenddown · 1.69

RSI (14)51

MACD hist0.02

MACD crossbull · 5d

Stoch %K / %D69 / 65

ADX (14)11

+DI / −DI26 / 16

RSI divergence—

MACD divergence—

ATR %+6.40%

ADR %6.20%

52w high8.10

52w low1.35

From 52w high-81.23%

Above 52w low+12.59%

New 52w highNo

SqueezeOff

Bollinger width23.72%

%B0.57

Donchian pos32.71%

Donchian high1.88

Donchian low1.35

AVWAP (52w high)4.80

vs AVWAP high-68.31%

AVWAP (52w low)4.45

vs AVWAP low-65.84%

OBV trendFlat

Chaikin MF (20)0.17

Today vs 20d0.20×

Avg vol (14d)82.18K

Avg vol (20d)87.86K

Avg $ vol (20d)133.03K

Market cap—

RS 3m (vs SPY)-33.06%

RS 6m (vs SPY)-39.36%

RS line new highNo

Trend template0/8

Technical rank18.2

1 week+6.29%

1 month+1.33%

3 months-27.27%

6 months-30.59%

1 year-67.31%

YTD-44.93%

P/E-0.84

P/B0.96

P/S—

P/FCF—

EPS-5.32

Div yield—

ROE-113.59%

ROA-83.51%

Debt/Eq—

Current2.44

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth43.51%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value-7.75M

Revenue—

Net income-1.68M

Gross profit—

Free cash flow—

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out4.3M

Employees4

ListedFri, Jun 25, 2021

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank18.2 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance1.82

Support1.34

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ACXP

All disclosures →

No recent disclosed trades by Congress in ACXP. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ACXP · 8 buys

Insider	Side	Shares	Value	Traded	Filed
LUCI DAVID P President and CEO · Stock Option · 2026-04-20	Grant	37.1K	$0	2026-04-20	2026-04-22
DELUCCIA ROBERT J Director · Stock Option · 2026-04-20	Grant	37.1K	$0	2026-04-20	2026-04-22
Scodari Joseph C Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22
Shawah Robert G. Chief Financial Officer · Stock Option · 2026-04-20	Grant	25.9K	$0	2026-04-20	2026-04-22
HARRISON THOMAS L Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22
Sailer Carl Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22
DEAN JACK H Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22
Donohue James J. Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22

SEC filings

EDGAR filings in ACXP

EDGAR →

No recent SEC filings on file for ACXP.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.